z-logo
open-access-imgOpen Access
Fulminant Myocarditis: Covid Or Not COVID? Reinfection Or co-infection?
Author(s) -
Ramya Yeleti,
Maya Guglin,
Kashif Saleem,
Sasikanth Adigopula,
Anjan Sinha,
Smrity Upadhyay,
Jeffrey E. Everett,
Kareem Ballut,
Sarada Uppuluri,
Roopa A. Rao
Publication year - 2021
Publication title -
future cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.392
H-Index - 33
eISSN - 1744-8298
pISSN - 1479-6678
DOI - 10.2217/fca-2020-0237
Subject(s) - medicine , covid-19 , fulminant , myocarditis , virology , betacoronavirus , pandemic , outbreak , infectious disease (medical specialty) , disease
We describe a unique case of fulminant myocarditis in a patient with presumed SARS-CoV-2 reinfection. Patient had initial infection 4 months backand had COVID-19 antibody at the time of presentation. Endomyocardial biopsy showed lymphocytic myocarditis, that is usually seen in viral myocarditis. The molecular diagnostic testing of the endomyocardial biopsy for cardiotropic viruses was positive for Parvovirus and negative for SARS-CoV-2. Authors highly suspect co-infection of SARS-CoV-2 and Parvovirus, that possibly triggered the immune cascade resulting in fulminant myocarditis. Patient was hemodynamically unstable with ventricular tachycardia and was supported on VA ECMO and Impella CP. There was impressive recovery of left ventricular function within 48 hours, leading to decannulation of VA ECMO in 72 h. This unique case was written by the survivor herself.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom